In addition to preclinical studies, there are several case studies reporting that individuals with HER2-mutant metastatic lung or breast cancer respond to trastuzumab, trastuzumab + pertuzumab, or neratinib [94–97]. This evidence concerns the gene ERBB2 and breast cancer.